There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .
Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study
The efficacy of amisulpride in depressive disorders has been demonstrated in dysthymia and in double depression . Limited data are available in major depression . A r and omized , double-blind , parallel group , multicentre study was set up to compare the efficacy and tolerability of amisulpride ( 50 mg o.d . ) and paroxetine ( 20 mg o.d . ) for 8 weeks in 272 patients with major depression ( DSM-IV and baseline Hamilton Depression Rating Scale ( HAMD ) score ≥18 ) . The study was design ed as a non-inferiority trial based on the proportion of responders ( ≥50 % decrease in HAMD total score ) at end-point , with a maximal allowable difference of 15 % ; secondary end-points included HAMD total and cluster scores , Montgomery and Asberg Depression Rating Scale score and responders rates and Clinical Global Impression improvement . The tolerability evaluation was based on incidence of adverse events and routine laboratory tests . The results did not disclose statistically significant differences between treatments , although the hypothesis of an efficacy difference between the two treatments within the set limit at day 56 could not be accepted . The issue of non-inferiority trials is discussed
There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .